| Literature DB >> 33569196 |
Francesco Puccetti1, Andrea Cossu1, Paolo Parise1, Lavinia Barbieri1, Ugo Elmore1, Agnese Carresi1, Stefano De Pascale2, Uberto Fumagalli Romario2, Riccardo Rosati1.
Abstract
BACKGROUND: Esophageal cancer surgery has historically been associated with high levels of postoperative morbidity and mortality. Post-esophagectomy diaphragmatic hernia (PEDH) represents a potentially life-threatening surgical complication, with incidence and risk factors not clearly demonstrated. This study evaluates presenting characteristics and repair outcomes in PEDH after Ivor Lewis esophagectomy for cancer.Entities:
Keywords: Hiatal hernia; esophageal cancer; esophagectomy; postoperative complications
Year: 2021 PMID: 33569196 PMCID: PMC7867823 DOI: 10.21037/jtd-20-1974
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 2.895
Study population demographics
| Characteristic | PEDH (n=22) | Non-PEDH (n=392) | P value |
|---|---|---|---|
| Gender | |||
| Male/female | 21/1 | 328/64 | 0.12 |
| Age (years), mean ± SD | 62±9.7 | 64±10.6 | |
| History of GERD, n (%) | |||
| With hiatal hernia | 0 (0.0) | 10 (2.6) | 0.45 |
| With Barrett metaplasia | 9 (40.9) | 110 (28.1) | 0.19 |
| ASA, n (%) | 0.18 | ||
| I | 1 (4.5) | 33 (8.4) | |
| II | 17 (77.3) | 222 (56.6) | |
| III | 3 (13.6) | 128 (32.7) | |
| IV | 1 (4.5) | 9 (2.3) | |
| Comorbidities, range | |||
| aa-CCI† | 3 (2 to 4) | 3 (2 to 4) | 0.48 |
| Nutritional status | |||
| Mean BMI (±SD), kg/m2 | 24.5±3.3 | 25.7±3.3 | 0.65 |
| Histology, n (%) | 0.38 | ||
| ADC | 19 (86.4) | 274 (69.9) | |
| SCC | 2 (9.1) | 90 (23.0) | |
| Neuroendocrine | 0 (0.0) | 3 (0.8) | |
| Undifferentiated | 0 (0.0) | 19 (4.8) | |
| Other | 1 (4.5) | 6 (1.5) | |
| Location, n (%) | 0.80 | ||
| Middle third | 3 (13.6) | 77 (19.6) | |
| Lower third | 4 (18.2) | 75 (19.1) | |
| EGJ | 15 (68.2) | 240 (61.2) | |
| Neoadjuvant therapy, n (%) | 0.05 | ||
| None | 6 (27.3) | 158 (40.3) | |
| Chemotherapy | 2 (9.1) | 86 (21.9) | |
| Chemoradiotherapy | 14 (63.6) | 148 (37.8) | |
| p/yp T stage, n (%) | 0.02 | ||
| T0/is | 8 (36.4) | 45 (11.5) | |
| T1 | 4 (18.2) | 77 (19.6) | |
| T2 | 2 (9.1) | 86 (21.9) | |
| T3 | 8 (36.4) | 167 (42.6) | |
| T4 | 0 (0.0) | 17 (4.3) | |
| p/yp N stage, n (%) | 0.66 | ||
| N0 | 10 (45.5) | 155 (39.5) | |
| N+ | 12 (54.5) | 237 (60.5) | |
| LN harvest†, range | 39 (25.0 to 43.5) | 32 (22.3 to 43.0) | 0.01 |
| LN ratio†, range | 0.01 (0.00 to 0.07) | 0.03 (0.00 to 0.11) | 0.83 |
| Operative technique, n (%) | 0.30 | ||
| Open | 3 (13.6) | 100 (25.5) | |
| Hybrid | 13 (59.1) | 226 (57.7) | |
| Totally (MIL) | 6 (27.3) | 66 (16.8) | |
| Postoperative morbidity, n (%) | |||
| Severe complications‡ | 6 (27.3) | 131 (33.4) | 0.65 |
| Reoperation | 3 (13.6) | 31 (7.39) | 0.41 |
| Mean operative time (min), mean ± SD | 279±49 | 271±68 | 0.49 |
†, median (inter quartile range); ‡, all complications consistent with grade ≥3a according to Clavien-Dindo classification. PEDH, post-esophagectomy diaphragmatic hernia; aa-CCI, age-adjusted Charlson Comorbidity Index.
Surgical outcomes after PEDH repair
| Characteristic | PEDH (n=22) |
|---|---|
| Primary tumor site, n (%) | |
| Middle third | 3 (13.6) |
| Lower third | 4 (18.2) |
| S1 | 6 (27.3) |
| S2 | 9 (40.9) |
| Mean interval to diagnosis (±SD) | 8±9.8 |
| Setting | |
| Urgent | 16 (72.7) |
| Elective | 6 (27.3) |
| PEDH contents, n (%) | |
| Colon | 15 (68.2) |
| Small bowel | 1 (4.5) |
| Both | 6 (27.3) |
| Surgical repair, n (%) | |
| Laparoscopic approach | 17 (77.3) |
| Conversion rate | 4 (23.5) |
| Cruroplasty | 21 (95.5) |
| Cruroplasty + mesh | 1 (4.5) |
| Postoperative morbidity, n (%) | |
| Atrial fibrillation | 1 (4.5) |
| Pneumonia | 1 (4.5) |
| Respiratory failure | 3 (13.6) |
| Early recurrence | 0 (0.0) |
| Median length of hospital stay (range) | 6 (2 to 95) |
| 30-day mortality, n (%) | 1 (4.5) |
| Recurrence rate, n (%) | 3 (13.6) |
PEDH, post-esophagectomy diaphragmatic hernia.
Univariate and Multivariate logistic regression of risk factors
| Characteristic | Univariate analyses | Multivariate analyses | |||
|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| Male | 4.329 (0.572–32.741) | 0.122 | |||
| Age >60 years | 0.830 (0.346–1.989) | 0.675 | |||
| BMI >25 kg/m2 | 0.941 (0.398–2.220) | 0.889 | |||
| ASA III–IV | 0.414 (0.137–1.246) | 0.106 | |||
| Neoadjuvant chemotherapy | 0.356 (0.082–1.552) | 0.152 | |||
| Neoadjuvant chemoradiotherapy | 2.885 (1.182–7.042) | 0.016 | 2.403 (0.951–6.072) | 0.064 | |
| Adenocarcinoma subtype | 2.107 (0.698–6.355) | 0.177 | |||
| Barrett metaplasia | 1.775 (0.738–4.270) | 0.195 | |||
| EGJ localization | 1.372 (0.547–3.442) | 0.499 | |||
| pT0 | 4.406 (1.752–11.084) | 0.001 | 3.616 (1.384–9.449) | 0.009 | |
| pT3-4 | 0.646 (0.265–1.575) | 0.333 | |||
| Lymph node count >33 | 2.894 (1.109–7.549) | 0.024 | 3.029 (1.140–8.049) | 0.026 | |
| OIL | 0.461 (0.134–1.591) | 0.210 | |||
| HIL | 1.061 (0.443–2.541) | 0.894 | |||
| MIL | 1.852 (0.699–4.910) | 0.209 | |||
| Severe morbidity (CD ≥3a)‡ | 0.747 (0.286–1.954) | 0.551 | |||
| Reoperation‡ | 1.839 (0.515–6.559) | 0.341 | |||
‡, after esophagectomy. CD, Clavien-Dindo scoring system.